Leland Gershell
Stock Analyst at Oppenheimer
(4.45)
# 286
Out of 4,944 analysts
140
Total ratings
47.33%
Success rate
25.38%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $28 → $32 | $18.91 | +69.27% | 6 | Aug 7, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $81.14 | +35.57% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $50.38 | +21.08% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $432.52 | +13.29% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $4.74 | +321.94% | 1 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $97.95 | +12.30% | 2 | Jul 10, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $8.30 | +165.06% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $191.15 | +17.19% | 12 | Jun 13, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $10 → $31 | $20.11 | +54.15% | 11 | Jun 13, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $10 | $1.63 | +513.50% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $7.28 | -3.85% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $646.60 | +9.50% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.72 | +481.40% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $7.60 | +163.16% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $58.30 | +68.10% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $20.86 | +149.34% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $3.41 | +1,366.28% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.92 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $15.89 | +233.54% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.68 | +715.22% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.16 | +455.56% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $4.55 | +109,790.11% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.28 | +662.20% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $30.09 | +142.61% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.35 | +751.06% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $20.19 | +43.64% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $9.08 | +285.67% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.81 | +1,134.11% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.16 | +1,624.14% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.74 | +647.13% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $2.93 | +3,995.56% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.65 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.54 | +67,189,149.72% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $17.21 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.89 | +2,545.50% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.90 | - | 5 | Mar 31, 2020 |
Viridian Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $18.91
Upside: +69.27%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $81.14
Upside: +35.57%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $50.38
Upside: +21.08%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $432.52
Upside: +13.29%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $4.74
Upside: +321.94%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $97.95
Upside: +12.30%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $8.30
Upside: +165.06%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $191.15
Upside: +17.19%
UroGen Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $20.11
Upside: +54.15%
Climb Bio
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.63
Upside: +513.50%
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $7.28
Upside: -3.85%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $646.60
Upside: +9.50%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.72
Upside: +481.40%
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $7.60
Upside: +163.16%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $58.30
Upside: +68.10%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.86
Upside: +149.34%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $3.41
Upside: +1,366.28%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.92
Upside: -
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $15.89
Upside: +233.54%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.68
Upside: +715.22%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.16
Upside: +455.56%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $4.55
Upside: +109,790.11%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.28
Upside: +662.20%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $30.09
Upside: +142.61%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.35
Upside: +751.06%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $20.19
Upside: +43.64%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $9.08
Upside: +285.67%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.81
Upside: +1,134.11%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.16
Upside: +1,624.14%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.74
Upside: +647.13%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $2.93
Upside: +3,995.56%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.65
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.54
Upside: +67,189,149.72%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $17.21
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.89
Upside: +2,545.50%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.90
Upside: -